newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved